Cerebrolysin

An injectable mixture of low-molecular-weight peptides derived from pig brain tissue, used in parts of Europe and Asia for stroke and dementia. Marketed online to biohackers as a cognition/neuro-repair agent.

Cerebrolysin is not a single molecule — it is a mixture of low-molecular-weight peptides and amino acids produced by enzymatically breaking down purified pig brain protein. That origin is worth stating plainly because it is rarely made obvious in the marketing. The claimed mechanism is neurotrophic: that the peptide fragments mimic the action of the body's own nerve growth factors, supporting neuron survival and repair. It is given by injection because a peptide mixture would not survive digestion. The mechanism is plausible and long-argued; what has never been resolved is whether it produces a clinically meaningful result in people.

Dozens of trials exist for stroke and Alzheimer's — but Cochrane reviews rate the evidence low-quality with unclear benefit: some trials show modest functional improvement, publication quality is weak, and Western regulators have never been persuaded. For cognitive enhancement in HEALTHY people, controlled evidence is essentially nonexistent.

• It has a substantial trial literature, which distinguishes it from most compounds in this catalogue — mostly in stroke, traumatic brain injury and dementia, and mostly from central and eastern Europe and Asia.
• The findings are genuinely mixed. The 2023 Cochrane review in acute ischaemic stroke found little or no difference in all-cause death across six trials and 1,689 participants, and notably NONE of the included studies reported the prespecified death-or-dependence outcome at all. Most trials were sponsored by the manufacturer.
• Some trials and meta-analyses in traumatic brain injury and vascular dementia report benefit on cognitive scales; the quality, independence and geographic concentration of that evidence are recurring criticisms.
• On safety in that same review: total serious adverse events did not differ significantly, but NON-FATAL serious adverse events were roughly doubled — 20 of 667 against 8 of 668. That is the safety signal, and it is not dizziness and agitation.
• It is approved as a prescription medicine in some countries, including national authorisations in Europe, and is not FDA-registered or approved for US sale. That is a statement of status — it does not establish that any Western regulator reviewed and rejected an application.
• There is no evidence at all for its use as a nootropic in healthy people, which is the use most people in this space are considering.

A peptide mixture given by intramuscular or intravenous injection; it cannot work orally. Because it is a biological preparation rather than a defined chemical, batch-to-batch consistency depends entirely on the manufacturer — and product bought outside a regulated supply chain carries no assurance of what it contains or whether it is sterile. Injecting a non-sterile biological preparation is its own category of risk, independent of the drug.

As an injectable biological product bought gray-market: sterility, provenance, and prion-theoretical concerns dwarf the drug's own side-effect profile (dizziness, agitation reported in trials). Injecting animal-derived biologics of unknown handling is a categorically different risk class from a mislabeled pill.

• Anyone considering it as a cognitive enhancer, since there is no evidence for that use
• Anyone with epilepsy or a seizure history
• Anyone with severe kidney impairment
• Anyone pregnant or breastfeeding
• Anyone sourcing it outside a regulated supply chain, given it is an injectable biological

• MAO inhibitors and some antidepressants, which the manufacturer's labelling advises against combining with it.
• Anything relying on a sterile preparation — this is an injectable biological and contamination risk is real.
• No well-characterised drug interaction profile exists, which is itself a limitation rather than a reassurance.

• Its recognised contraindications are hypersensitivity, epilepsy and severe kidney impairment — those come from the product monograph and belong up front.
• Injection site and any sign of infection. With grey-market product the practical hazards are sterility, contamination, authenticity and uncontrolled injection.
• Allergic and hypersensitivity reactions, which are the reported adverse events of note for a foreign-protein-derived preparation.
• Any seizure activity, since seizures have been reported.
• Whether the product came from a regulated supply chain at all — with a biological, this matters more than with a small molecule.

It is given in courses rather than continuously, so stopping is the normal end of a course rather than an event. No withdrawal syndrome is described. Any benefit reported in the trial literature was measured during and shortly after treatment courses, and there is no evidence about what persists afterwards. Anyone who developed a hypersensitivity reaction should treat that as a reason not to repeat it, and should tell any future clinician.

Approved as a prescription medicine in some countries, including national authorisations in parts of Europe and Asia. NOT approved or registered in the US; personal importation of an unapproved drug is generally illegal, with narrow case-by-case FDA enforcement discretion.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Cerebrolysin for acute ischaemic stroke
  Cochrane Database Syst Rev, 2023
• Cerebrolysin for vascular dementia
  Cochrane Database Syst Rev, 2019

• Cerebrolysin for acute ischaemic strokeCochrane Database Syst Rev · 2023
• Cerebrolysin for vascular dementiaCochrane Database Syst Rev · 2019
• Cerebrolysin for acute ischaemic strokeCochrane Database Syst Rev · 2020
• Cerebrolysin in Patients with TBI: Systematic Review and Meta-AnalysisBrain Sci · 2023
• Cerebrolysin for acute ischaemic strokeCochrane Database Syst Rev · 2017
• Cerebrolysin: a multi-target drug for recovery after strokeExpert Rev Neurother · 2018
• Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-AnalysisJ Clin Med · 2023
• Cerebrolysin for acute ischaemic strokeCochrane Database Syst Rev · 2015
• Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's diseaseProg Brain Res · 2019
• Cerebrolysin for vascular dementiaCochrane Database Syst Rev · 2013
• Cerebrolysin: a review of its use in dementiaDrugs Aging · 2009
• Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomesNeurol Sci · 2021